Modern strategies and capabilities for activation of the immune response against tumor cells

Tumor Biology

Volumn 39, Issue 5, 2017, Pages

  Sennikov, Sergey Vital’evich ^a   Khantakova, Julia Nikolaevna ^a   Kulikova, Ekaterina Vladimirovna ^a   Obleukhova, Irina Alexandrovna ^a   Shevchenko, Julia Alexandrovna ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

Author keywords

Antitumor immune response; Cancer; Dendritic cells

Indexed keywords

DIFFERENTIATION ANTIGEN; DNA; ONCOFETAL ANTIGEN; RNA; TESTICULAR CANCER ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; GENE PRODUCT; HELPER CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; T-LYMPHOCYTES;

EID: 85019974246     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317698380     Document Type: Review

References (73)

1. Reiman JM, Kmieciak M, Manjili MH, et al. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007; 17: 275-287.
2. Evans C, Dalgleish AG and Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006; 24(8): 1163-1177.
3. Nakayama H, Kitayama J, Muto T, et al. Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol 2000; 30(7): 301-305.
4. Becker JC, Andersen MH, Schrama D, et al. Immunesuppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013; 62: 1137-1148.
5. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22.
6. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166(1): 678-689.
7. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6(5): 1755-1766.
8. Pinzon-Charry A, Maxwell T and López JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 451-461.
9. Fricke I and Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006; 35: 459-483.
10. Benencia F, Sprague L, McGinty J, et al. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012; 2012: 425476.
11. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
12. Finn OJ, Binder RJ, Brickner AG, et al. Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O and Seliger B (eds) Tumor-associated antigens: identification, characterization, and clinical applications. Weinheim: WILEY-VCH Verlag GmbH and Co. KGaA, 2009, pp. 23-43.
13. Viehl CT, Tanaka Y, Chen T, et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res Treat 2005; 91(3): 271-278.
14. Grube M, Moritz S, Obermann EC, et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007; 13: 1053-1060.
15. Soto AM and Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 2011; 33: 332-340.
16. Mueller MM and Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-849.
17. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117(5): 1195-1203.
18. Grazino DF and Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat Res 2005; 123: 89-111.
19. Novellino L, Castelli C and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207.
20. Ilyas S and Yang JC. Landscape of tumor antigens in T cell immunotherapy. J Immunol 2015; 195(11): 5117-5122.
21. Palucka K, Ueno H, Fay J, et al. Dendritic cells and immunity against cancer. J Intern Med 2011; 269(1): 64-73.
22. McNamara MA, Nair SK and Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015; 2015: 794528.
23. Peres Lde P, da Luz FA, Pultz Bdos A, et al. Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv 2015; 33(8): 1868-1877.
24. Ugel S, Facciponte JG, De Sanctis F, et al. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother 2015; 64(10): 1339-1348.
25. Janikashvili N, Larmonier N and Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy 2010; 2(1): 57-68.
26. Marchini C, Kalogris C, Garulli C, et al. Tailoring DNA vaccines: designing strategies against HER2-positive cancers. Front Oncol 2013; 3: 122.
27. Dong H, Dai G, Xu L, et al. Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes. Mol Med Rep 2014; 10: 2827-2834.
28. Palucka K, Ueno H and Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186(3): 1325-1331.
29. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673): 245-252.
30. Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res 2013; 1(3): 145-149.
31. Kulikova AV, Kurilin VV, Schevchenko JA, et al. Dendritic cells transfected with a DNA construct encoding tumourassociated antigen epitopes induce a cytotoxic immune response against autologous tumour cells in a culture of mononuclear cells from colorectal cancer patients. Scand J Immunol 2015; 82(2): 110-117.
32. Sennikov SV, Shevchenko JA, Kurilin VV, et al. Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients. Immunol Res 2016; 64(1): 171-180.
33. Obleukhova IA, Kurilin VV, Goncharov MA, et al. Effect of mature dendritic cells primed with autologous tumor antigens from patients with epithelial ovarian cancer on stimulation of the cytotoxic immune response in culture of mononuclear cells. Bull Exp Biol Med 2013; 156(1): 161-164.
34. Markiewicz MA and Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest 2004; 22: 417-434.
35. Liu LN, Shivakumar R, Allen C, et al. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol 2008; 423: 139-153.
36. Bohnenkamp HR, Coleman J, Burchell JM, et al. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHCclass-I tetramers. Cell Immunol 2004; 231: 112-125.
37. Kass R, Bellone S, Palmieri M, et al. Restoration of tumorspecific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 2003; 80: 275-285.
38. Delirezh N, Moazzeni SM, Shokri F, et al. Autologous dendritic cells loaded with apoptotic tumor cells induce T cellmediated immune responses against breast cancer in vitro. Cell Immunol 2009; 257: 23-31.
39. Nagaraj S, Pisarev V, Kinarsky L, et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007; 30(2): 169-179.
40. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113(11): 1515-1525.
41. Ladjemi MZ, Jacot W, Chardès T, et al. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59(9): 1295-1312.
42. Yang H, Cho N-H and Seong S-Y. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours. Clin Exp Immunol 2009; 158: 174-185.
43. Zhou Y, Bosch ML and Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002; 25: 289-303.
44. Pol J, Bloy N, Buqué A, et al. Trial Watch: peptide-based anticancer vaccines. Oncoimmunology 2015; 4(4): e974411.
45. Kibe S, Yutani S, Motoyama S, et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res 2014; 2(12): 1154-1162.
46. Sakai K, Shimodaira S, Maejima S, et al. Dendritic cellbased immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123(4): 989-997.
47. Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20(9): 2433-2444.
48. Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 258(6): 879-886.
49. Koski GK, Koldovsky U, Xu S, et al. A novel dendritic cellbased immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 2012; 35(1): 54-65.
50. Knutson KL, Schiffman K, Cheever MA, et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8(5): 1014-1018.
51. Mittendorf EA, Holmes JP, Murray JL, et al. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009; 9(1): 71-78.
52. Kirk CJ and Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11: 797-806.
53. Bonehill A, Van Nuffel AM, Corthals J, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009; 15: 3366-3375.
54. Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011; 34: 448-456.
55. Markov OV, Mironova NL and Sennikov SV. Prophylactic dendritic cell-based vaccines efficiently inhibit metastases in murine metastatic melanoma. PLoS One 2015; 10(9): e0136911.
56. Markov OV, Mironova NL and Shmendel EV. Multicomponent mannose-containing liposomes efficiently deliver RNA in murine immature dendritic cells and provide productive anti-tumour response in murine melanoma model. J Control Release 2015; 213: 45-56.
57. Benteyn D, Van Nuffel AM, Wilgenhof S, et al. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013; 2013: 976383.
58. Van Nuffel AM, Benteyn D, Wilgenhof S, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20: 1063-1074.
59. Nakamura M, Iwahashi M, Nakamori M, et al. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 2005; 68: 163-170.
60. Josefsberg JO and Buckland B. Vaccine process technology. Biotechnol Bioeng 2012; 109(6): 1443-1460.
61. Bolhassani A, Safaiyan S and Rafati S. Review: improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 2011; 10(1): 3.
62. Maksyutov AZ, Lopatnikova YA, Kurilin VV, et al. A study of the efficacy of cytotoxic immune response induction by mononuclear cells using dendritic cells transfected with HER2/ErbB2 polyepitopic constructs. Med Immunol 2014; 16(5): 417-424.
63. Boudreau JE, Bonehill A, Thielemans K, et al. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011; 19(5): 841-853.
64. Douek D and Nabel G. Vaccines. Immunol Rev 2011; 239: 5-7.
65. Luo D and Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-37.
66. Lundqvist A, Noffz G, Pavlenko M, et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2002; 25: 445-454.
67. Voskoboinik I, Dunstone MA, Baran K, et al. Perforin: structure, function, and role in human immunopathology. Immunol Rev 2010; 235(1): 35-54.
68. Schulze-Osthoff K, Ferrari D, Los M, et al. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439-459.
69. Malyguine AM, Strobl SL and Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother 2012; 61(2): 239-247.
70. Shevchenko YA, Khantakova YN, Kurilin VV, et al. Stimulation of a cytotoxic immune response in a culture of mononuclear cells in breast cancer patients using dendritic cells loaded with tumor lysate antigens. Immunologiya 2013; 34(6): 327-330.
71. Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1(7): 1111-1134.
72. Di L, Zhu Y, Jia J, et al. Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin Transl Oncol 2012; 14(9): 675-681.
73. Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl) 2012; 125(21): 3771-3777.